Language:English
Language:

Xcessbio

Place your promotion here

You have no items in your shopping cart.

MK-1775 (AZD1775), WEE1 Inhibitor

MK-1775 (AZD1775), WEE1 Inhibitor

$129.00
A highly potent, selective and orally bioavailable Wee1 kinase inhibitor.
Catalog No. Unit Price Qty
M60299-2s 2 mg solid $129.00

Details

Product Information
Molecular Weight: 500.61
Formula: C27H32N8O2
Purity: ≥98%
CAS#: 955365-80-7
Solubility: DMSO up to 100 mM
Chemical Name: 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

MK-1775 (AZD1775) is a highly potent, selective and orally bioavailable Wee1 kinase inhibitor with IC50 of 5.2 nM. It abrogated DNA damaged checkpoints induced by gemcitabine, carboplatin, and cisplatin etc. and enhanced the anti-tumor efficacy of these agents selectively in p53-deficient tumor cells. At tolerated doses, MK-1775 treatment leads to xenograft tumor growth inhibition or regression. It inhibits Wee1 in H3K36me3-deficient cells results in RRM2 reduction, critical dNTP depletion, S-phase arrest, and apoptosis. MK-1775 can regresse H3K36me3-deficient tumor xenografts too. Right now MK-1775 is in phase I/II clinical trials for various cancers.

How to Use:

In vitro: MK-1775 was used at 1 µM in vitro and cellular assays.
In vivo: MK-1775 was orally dosed to mice at 20 mg/Kg once per day.

Reference:

  • 1. Hirai H, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. (2009) Mol Cancer Ther. 8(11):2992-3000.
  • 2. Rajeshkumar NV, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. (2011) Clin Cancer Res. 17(9):2799-806. 
  • 3. Guertin AD, et al. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. (2013) Mol Cancer Ther. 12(8):1442-52. 
  • 4. Pfister SX, et al. Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation. (2015) Cancer Cell. 28(5):557-68.

MK-1775_spec.pdf      
MK-1775_MSDS.pdf      


Products are for research use only. Not for human use. 

Description

Details

Product Information
Molecular Weight: 500.61
Formula: C27H32N8O2
Purity: ≥98%
CAS#: 955365-80-7
Solubility: DMSO up to 100 mM
Chemical Name: 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

MK-1775 (AZD1775) is a highly potent, selective and orally bioavailable Wee1 kinase inhibitor with IC50 of 5.2 nM. It abrogated DNA damaged checkpoints induced by gemcitabine, carboplatin, and cisplatin etc. and enhanced the anti-tumor efficacy of these agents selectively in p53-deficient tumor cells. At tolerated doses, MK-1775 treatment leads to xenograft tumor growth inhibition or regression. It inhibits Wee1 in H3K36me3-deficient cells results in RRM2 reduction, critical dNTP depletion, S-phase arrest, and apoptosis. MK-1775 can regresse H3K36me3-deficient tumor xenografts too. Right now MK-1775 is in phase I/II clinical trials for various cancers.

How to Use:

In vitro: MK-1775 was used at 1 µM in vitro and cellular assays.
In vivo: MK-1775 was orally dosed to mice at 20 mg/Kg once per day.

Reference:

  • 1. Hirai H, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. (2009) Mol Cancer Ther. 8(11):2992-3000.
  • 2. Rajeshkumar NV, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. (2011) Clin Cancer Res. 17(9):2799-806. 
  • 3. Guertin AD, et al. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. (2013) Mol Cancer Ther. 12(8):1442-52. 
  • 4. Pfister SX, et al. Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation. (2015) Cancer Cell. 28(5):557-68.

MK-1775_spec.pdf      
MK-1775_MSDS.pdf      


Products are for research use only. Not for human use. 

Reviews

Write Your Review

How do you rate this product? *

Price:
Value:
Quality: